Targeting ferroptosis in osteosarcoma

Jiazheng Zhao; Yi Zhao; Xiaowei Ma; Benzheng Zhang; Helin Feng

doi:10.1016/j.jbo.2021.100380

Targeting ferroptosis in osteosarcoma

J Bone Oncol. 2021 Jul 12:30:100380. doi: 10.1016/j.jbo.2021.100380. eCollection 2021 Oct.

Authors

Jiazheng Zhao¹, Yi Zhao¹, Xiaowei Ma¹, Benzheng Zhang², Helin Feng¹

Affiliations

¹ Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang, Hebei 050011, PR China.
² Hebei Medical University, 361 Zhongshan East Road, Shijiazhuang, Hebei 050011, PR. China.

Abstract

Osteosarcoma (OS) is the most common primary bone tumour in children and adolescents, with high degree of malignancy and an extremely poor prognosis. Ferroptosis, a non-traditional mode of regulated cell death (RCD) characterised by iron-dependent accumulation of lipid reactive oxygen species (ROS), is closely associated with a variety of cancers. It has been demonstrated that ferroptosis can regulate OS progression and exert an essential role in the treatment of OS, which is potentially of great value. By targeting ferroptosis in OS, the present review article summarises the relevant mechanisms and therapeutic applications along with discussing current limitations and future directions, which may provide a new strategy for the treatment of OS.

Keywords: Ferroptosis; Iron; Osteosarcoma; Reactive oxygen species; Treatment.

Publication types

Review